Evidence map›Paper›PMID 41362817›Full record

ArticleGastro hep advances2026

Plasma Fibulin-5 as a Novel Marker for Advanced Fibrosis in Chronic Hepatitis C.

Yutaka Yasui, Misako Sato-Matsubara, Masaru Enomoto, Tsutomu Matsubara, Mana Kosugi, Kirara Inoue, Truong Huu Hoang, Hideto Yuasa, Hideki Fujii, Atsuko Daikoku and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yutaka YasuiDepartment of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Misako Sato-MatsubaraDepartment of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Masaru EnomotoDepartment of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Tsutomu MatsubaraDepartment of Anatomy and Regenerative Biology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Mana KosugiDepartment of Anatomy and Regenerative Biology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Kirara InoueDepartment of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Truong Huu HoangCentre for Genetic Consultation and Cancer Screening, 108 Military Central Hospital, Hanoi, Vietnam.
Hideto YuasaDepartment of Anatomy and Regenerative Biology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Hideki FujiiDepartment of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Atsuko DaikokuDepartment of Anatomy and Regenerative Biology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Yoshihiro IkuraDepartment of Pathology, Takatsuki General Hospital, Takatsuki, Japan.
Etsushi KawamuraDepartment of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Sawako Uchida-KobayashiDepartment of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Akihiro TamoriDepartment of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Norifumi KawadaDepartment of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: Despite remarkable advances in the treatment of viral hepatitis, liver fibrosis sometimes persists after viral eradication. The accumulation of elastic fiber is associated with unfavorable clinical outcomes. We aimed to clarify the utility of plasma fibulin-5 (FBLN5), a component of elastic fibers, in assessing liver fibrosis in patients with chronic hepatitis. Methods: We reviewed 90 patients with chronic hepatitis C who underwent liver biopsy. Using immunohistochemistry and in situ hybridization, we investigated the localization of FBLN5 and its correlation with α-smooth muscle actin (αSMA). We then analyzed mRNA and protein expression in human hepatic stellate cells (HHSteCs) and primary mouse stellate cells. Lastly, we evaluated the utility of plasma FBLN5 for predicting liver fibrosis in patients with hepatitis C. Results: Immunohistochemical analysis revealed a correlation between the quantity of FBLN5 and αSMA ( Conclusion: FBLN5 may represent the activation of hepatic stellate cells, and plasma FBLN5 levels have the potential to predict advanced fibrosis, especially in fibrosis related to elastic fibers.

Indexed as

Activated Hepatic Stellate CellsCirrhosisElastic FiberLiver Fibrosis

Identifiers

PMID41362817
PMCPMC12681702

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.